EGFR-TKI联合化疗对晚期非小细胞肺癌患者血清IGF-1和AGR2水平的影响  

Effect of EGFR-TKI combined with chemotherapy on serum IGF-1 and AGR2 levels in patients with advanced non-small cell lung cancer

作　　者：岳红红[1] 赵亮[1] 姜威[1] 

机构地区：[1]中国武警总医院,北京100039

出　　处：《国际检验医学杂志》2016年第23期3277-3279,共3页International Journal of Laboratory Medicine

摘　　要：目的观察表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)联合化疗对非小细胞肺癌(NSCLC)患者化疗前后血清胰岛素样生长因子1(IGF-1)和前梯度蛋白2(AGR2)水平变化的影响,探讨IGF-1和AGR2能否作为评估NSCLC化疗疗效及预后的指标。方法选取68例晚期NSCLC患者给予EGFR-TKI联合化疗为试验组,并以30例健康人群为健康对照组,采用酶联免疫吸附试验(ELISA)分别测定化疗前、化疗3周后血清IGF-1、AGR2水平。采用Kanplan-Meier法分析血清IGF-1、AGR2水平变化对预后的影响。结果(1)EGFR-TKI联合化疗疾病控制率(DCR)为52.9%;(2)试验组治疗前血清IGF-1水平为(329.35±88.13)μg/L,明显高于健康对照组的(146.36±41.27)μg/L(P<0.01),试验组治疗前血清AGR2水平为(16.72±6.23)ng/mL,高于健康对照组的(4.38±2.17)ng/mL(P<0.01);治疗后血清IGF-1为(211.53±52.31)μg/L、AGR2水平为(9.72±3.56)ng/mL,均比治疗前明显降低(均P<0.01);NSCLC患者血清IGF-1与AGR2水平呈正相关(r=0.489,P<0.01);(3)治疗有效组患者血清IGF-1水平为(128.62±48.24)μg/L、AGR2水平为(7.22±4.27)ng/mL,分别较治疗前IGF-1[(334.23±82.11)μg/L]、AGR2[(18.43±6.17)ng/mL]明显下降(均P<0.01)。Kanplan-Meier分析显示,治疗后血清IGF-1、AGR2水平的高低对预后有明显影响。结论 IGF-1、AGR2水平在评估EGFR-TKI联合化疗对晚期NSCLC的疗效及预后有着潜在的临床价值。Objective To observe the effect of EGFR-TKI combined with chemotherapy on the changes of serum insulin-like growth factor1（IGF-1）and anterior gradient-2（AGR2）levels in the patients with advanced non-small cell lung cancer（NSCLC）,and to investigate whether IGF-1and AGR2 can serve as a potential indicator of the prognosis and efficacy of chemotherapy in NSCLC.Methods Sixty-eight patients with advanced NSCLC were selected as the experimental group treated by EGFR-TKI combined chemotherapy and 30 healthy people served as the healthy control group.（treatment group）.The levels of serum IGF-1and AGR2 before chemotherapy and at 3weeks after chemotherapy were detected by ELISA.The influence of serum IGF-1and AGR2 levels on the prognosis was analyzed by using Kanplan-Meier method.Results（1）The disease control rate（DCR）in the EGFR-TKI combined chemotherapy was 52.9%;（2）the level of serum IGF-1before treatment in the experimental group was（329.35±88.13）μg/L,which was significantly higher than（146.36±41.27）μg/L in the healthy control group（P〈0.01）;the level of serum AGR2 in experimental group was（16.72±6.23）ng/mL,which was significantly higher than（4.38±2.17）ng/mL in the healthy control group（P〈0.01）;serum levels of IGF-1and AGR2 after treatment were（211.53±52.31）μg/L and（9.72±3.56）ng/mL respectively,which were significantly lower than those before treatment（P〈0.01）;serum IGF-1and AGR2 in NSCLC patients were positively correlated（r=0.489,P〈0.01）;（3）serum levels of IGF-1and AGR2 after chemotherapy were（128.62±48.24）μg/L and（7.22±4.27）ng/mL respectively,which were obviously lower than（334.23±82.11）μg/L and（18.43±6.17）ng/mL before chemotherapy（all P〈0.01）.The Kanplan-Meier analysis revealed that serum IGF-1and AGR2 levels in advanced NSCLC had an obvious influence on the prognosis.Conclusion Serum IGF-l and AGR2 levels may have a potential clinical value to assess the therapeutic efficacy of EGFR-TKI combined chem

关 键 词：非小细胞肺癌 胰岛素样生长因子 前梯度蛋白2 预后 

分 类 号：R734.2[医药卫生—肿瘤]